For men with metastatic prostate cancer refractory to hormonal and chemotherapy, what is the efficacy and toxicity of radionuclide therapy with Lutetium-177 PSMA
Phase of Trial: Phase I/II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs PSMA 617 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Oct 2017 New trial record
- 02 Oct 2017 According to an Endocyte media release,updated results from the study are expected to be presented in 2018.
- 02 Oct 2017 According to an Endocyte media release, this trial has subsequently been expanded to 50 subjects from the original 30.